24-hour IOP monitoring

Article

A Swiss startup company, Sensimed, has developed a novel technology for measuring increases in intraocular pressure.

A novel technology for 24-hour IOP monitoring has been developed during which time the patient's movements are unrestricted. The system is designed to monitor intraocular pressure (IOP) continuously, up to 24 hours and comprises a soft hydrophilic silicone disposable contact lens embedding a MEMS sensor (micro electro-mechanical system) and a telemetry microprocessor.

Abnormal IOL is one of known causes of glaucoma. This behavior is individual, has transient peaks and varies significantly over a 24-hours period. The system, The Triggerfish, developed by a Swiss start-up company, SENSIMED, has received its CE mark and will undergo clinical trials during 2009 in key European centres. In the US it is under FDA review.

"With one of two glaucoma patients undiagnosed and one of three under inadequate treatment, we believe this will be a great contribution to help ophthalmologists diagnose and treat their glaucoma patients." said Jean-Marc Wismer, CEO of SENSIMED. "A better understanding of how pressure fluctuates during night and day in a patient suffering from glaucoma will lead, for the first time, to more efficient and personalized drug delivery. The breakthrough potential of the solution is enormous and confirmed by the eagerness of our key opinion leaders."

In addition to the medical device system, SENSIMED has developed a full, generic telemetry solution which can be adapted to interface various types of sensors for a variety of applications. The principle is to enable in situ measurement without physical connection or power supply on the sensing site. An external system will send RF (radio-frequency) power to the sensing site and receive in return measurement information.

www.sensimed.ch

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
© 2025 MJH Life Sciences

All rights reserved.